Follow this preprint
Simulation model for productivity, risk and GDP impact forecasting of the COVID-19 portfolio vaccines
Vladimir Shnaydman
doi: https://doi.org/10.1101/2020.11.01.20214122
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Vladimir Shnaydman
ORBee Consulting
PhD.
- Input data file[supplements/214122_file02.xlsx]
Posted November 04, 2020.
Simulation model for productivity, risk and GDP impact forecasting of the COVID-19 portfolio vaccines
Vladimir Shnaydman
medRxiv 2020.11.01.20214122; doi: https://doi.org/10.1101/2020.11.01.20214122
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (417)
- Allergy and Immunology (738)
- Anesthesia (216)
- Cardiovascular Medicine (3155)
- Dermatology (268)
- Emergency Medicine (468)
- Epidemiology (13122)
- Forensic Medicine (15)
- Gastroenterology (876)
- Genetic and Genomic Medicine (4946)
- Geriatric Medicine (456)
- Health Economics (758)
- Health Informatics (3112)
- Health Policy (1110)
- Hematology (416)
- HIV/AIDS (983)
- Medical Education (460)
- Medical Ethics (121)
- Nephrology (508)
- Neurology (4700)
- Nursing (249)
- Nutrition (696)
- Oncology (2426)
- Ophthalmology (690)
- Orthopedics (272)
- Otolaryngology (334)
- Pain Medicine (313)
- Palliative Medicine (88)
- Pathology (523)
- Pediatrics (1258)
- Primary Care Research (530)
- Public and Global Health (7269)
- Radiology and Imaging (1625)
- Respiratory Medicine (950)
- Rheumatology (464)
- Sports Medicine (408)
- Surgery (525)
- Toxicology (66)
- Transplantation (223)
- Urology (193)